Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The light-sensitive cation channel in retinal bipolar cells, specifically identified as TRPM1 (transient receptor potential melastatin 1), is a key ion channel expressed in the dendrites of ON bipolar cells in the retina. It opens in response to light-induced reduction in glutamate release from photoreceptors, allowing influx of cations such as sodium and calcium, which depolarizes the ON bipolar cell.[1][2][3] This channel is regulated by the metabotropic glutamate receptor mGluR6 (GRM6) via a G-protein signaling cascade: in darkness, glutamate activates mGluR6, closing the channel through G-protein inhibition, hyperpolarizing the cell; light decreases glutamate, reopening the channel for depolarization.[3][5] TRPM1 thus inverts the photoreceptor's hyperpolarizing light response into a depolarizing signal in ON bipolar cells, enabling parallel ON and OFF pathways for contrast detection and visual information processing.[1][2][6] Mutations in TRPM1 cause complete congenital stationary night blindness (cCSNB), where the ON pathway fails, impairing vision in low light without progressive degeneration.[3] No approved drugs directly target this channel, but its role in visual transduction positions it as a potential therapeutic target for retinal disorders, though challenges include specificity to avoid disrupting retinal circuitry.[3] The channel's structure features a non-selective permeability to monovalent and divalent cations, contributing to graded postsynaptic potentials without action potentials in bipolar cells.[1][5] It integrates with horizontal and amacrine cell feedback for center-surround receptive fields, enhancing spatial contrast.[2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Light-sensitive cation channel in retinal ON bipolar cells (TRPM1).